Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results

INTRODUCTION: Certolizumab pegol (CZP), an Fc-free, PEGylated anti-tumour necrosis factor biologic, dosed at 400 mg every 2 weeks (Q2W) and 200 mg Q2W over 16 weeks, resulted in improvements in Japanese patients with moderate to severe plaque psoriasis (PSO); no new safety signals were identified. W...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Dermatol Ther (Heidelb)
Huvudupphovsmän: Umezawa, Yoshinori, Asahina, Akihiko, Imafuku, Shinichi, Tada, Yayoi, Sano, Shigetoshi, Morita, Akimichi, Sakurai, Shinya, Hoshii, Naoki, Tilt, Nicola, Nakagawa, Hidemi
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Healthcare 2021
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8163922/
https://ncbi.nlm.nih.gov/pubmed/33886085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-021-00520-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk